病毒学报

[1] Zheng H, Wang Y, Wang F, et al. New progress in HBV control and the cascade of health care for people living with HBV in China:evidence from the fourth national serological survey, 2020[J]. Lancet Reg Health West Pac, 2024, 51:101193. DOI:10. 1016/j.lanwpc. 2024. 101193.

[2] Wu F, Lu R, Liu Y, et al. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers[J]. Liver Int, 2021, 41(9):2032-2045. DOI:10. 1111/liv. 14897.

[3] Hou J, Zhang W, Xie Q, et al. Xalnesiran with or without an immunomodulator in chronic hepatitis B[J].N Engl J Med, 2024, 391(22):2098-2109. DOI:10. 1056/NEJMoa2405485.

[4] Yuen MF, Heo J, Jang JW, et al. Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B:a phase2 randomized controlled trial[J]. Nat Med, 2021, 27(10):1725-1734. DOI:10. 1038/s41591-021-01513-4.

[5] Revill PA, Chisari FV, Block JM, et al. A global scientific strategy to cure hepatitis B[J]. Lancet Gastroenterol Hepatol, 2019, 4(7):545-558. DOI:10. 1016/S2468-1253(19)30119-0.

[6] Liu J, Yang HI, Lee MH, et al. Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma[J]. Gut, 2014, 63(10):1648-1657. DOI:10. 1136/gutjnl-2013-305785.

[7] Tout I, Loureiro D, Mansouri A, et al. Hepatitis B surface antigen seroclearance:Immune mechanisms,clinical impact, importance for drug development[J]. J Hepatol, 2020, 73(2):409-422. DOI:10. 1016/j.jhep. 2020. 04. 013.

[8] Gan W, Gao N, Gu L, et al. Reduction in intrahepatic cccDNA and integration of HBV in chronic hepatitis B patients with a functional cure[J]. J Clin Transl Hepatol, 2023, 11(2):314-322. DOI:10. 14218/JCTH. 2022. 00177.

[9] Lai CL, Wong D, Ip P, et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B[J]. J Hepatol,2017, 66(2):275-281. DOI:10. 1016/j.jhep. 2016. 08. 022.

[10]Kim GA, Lim YS, An J, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B:clinical outcomes and durability[J]. Gut,2014, 63(8):1325-1332. DOI:10. 1136/gutjnl-2013-305517.

[11]Zoulim F, Chen PJ, Dandri M, et al. Hepatitis B virus DNA integration:implications for diagnostics, therapy,and outcome[J]. J Hepatol, 2024, 81(6):1087-1099.DOI:10. 1016/j. jhep. 2024. 06. 037.

[12]Bonino F, Colombatto P, Brunetto MR. HBeAgnegative/anti-HBe-positive chronic hepatitis B:a 40-year-old history[J]. Viruses, 2022, 14(8):1691. DOI:10. 3390/v14081691.

[13]Tsai KN, Ou JJ. Hepatitis B virus e antigen and viral persistence[J]. Curr Opin Virol, 2021, 51:158-163.DOI:10. 1016/j. coviro. 2021. 10. 003.

[14]Jeng WJ, Papatheodoridis GV, Lok ASF. Hepatitis B[J]. Lancet, 2023, 401(10381):1039-1052. DOI:10. 1016/S0140-6736(22)01468-4.

[15]张锦茹，羊泽锐，蔡雪飞，等.乙肝病毒BCP区突变（A1762T/G1764A）对乙肝病毒复制的影响研究[J].病毒学报，2023, 39(3):710-719. DOI:10. 13242/j.cnki. bingduxuebao. 004300.

[16]Chu CJ, Lok AS. Clinical utility in quantifying serum HBV DNA levels using PCR assays[J]. J Hepatol,2002, 36(4):549-551. DOI:10. 1016/s0168-8278(02)00039-9.

[17]Naoumov NV, Lau JY, Daniels HM, et al. Detection of HBV-DNA using a digoxigenin-labelled probe. A rapid technique without loss of sensitivity[J]. J Hepatol, 1991, 12(3):382-385. DOI:10. 1016/0168-8278(91)90844-2.

[18]Martinot-Peignoux M, Boyer N, Colombat M, et al.Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers[J]. J Hepatol, 2002, 36(4):543-546. DOI:10. 1016/s0168-8278(02)00004-1.

[19]Loeb KR, Jerome KR, Goddard J, et al. Highthroughput quantitative analysis of hepatitis B virus DNA in serum using the TaqMan fluorogenic detection system[J]. Hepatology, 2000, 32(3):626-629. DOI:10. 1053/jhep. 2000. 9878.

[20]陈笑，谢垚，张苗，等. HBV-DNA试剂盒检测下限及线性范围下限精密度的性能评估[J].病毒学报，2022, 38(3):523-527. DOI:10. 13242/j. cnki.bingduxuebao. 004128.

[21]Candotti D, Assennato SM, Laperche S, et al.Multiple HBV transfusion transmissions from undetected occult infections:revising the minimal infectious dose[J]. Gut, 2019, 68(2):313-321. DOI:10. 1136/gutjnl-2018-316490.

[22]K?ck J, Theilmann L, Galle P, et al. Hepatitis B virus nucleic acids associated with human peripheral blood mononuclear cells do not originate from replicating virus[J]. Hepatology, 1996, 23(3):405-413. DOI:10. 1002/hep. 510230303.

[23]Pan J, Xu J, Luo H, et al. Factors and virological significance of hepatitis B virus pregenomic RNA status after 5 years of antiviral therapy[J]. Int J Infect Dis,2021, 105:418-423. DOI:10. 1016/j.ijid. 2021. 02. 116.

[24]Gao Y, Li Y, Meng Q, et al. Serum hepatitis B virus DNA, RNA, and HBsAg:which correlated better with intrahepatic covalently closed circular DNA before and after nucleos(t)ide analogue treatment?[J]. J Clin Microbiol, 2017, 55(10):2972-2982. DOI:10. 1128/JCM. 00760-17.

[25]Wang J, Shen T, Huang X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65(4):700-710. DOI:10. 1016/j. jhep. 2016. 05. 029.

[26]Liu S, Wu Y, Deng R, et al. Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients[J]. Antiviral Res, 2021, 189:105037. DOI:10. 1016/j.antiviral. 2021. 105037.

[27]Adraneda C, Tan YC, Yeo EJ, et al. A critique and systematic review of the clinical utility of hepatitis B core-related antigen[J]. J Hepatol, 2023, 78(4):731-741.DOI:10. 1016/j. jhep. 2022. 12. 017.

[28]Hwang SY, Yoo SH, Chang HY, et al. Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals[J]. J Viral Hepat, 2023, 30(1):39-45.DOI:10. 1111/jvh. 13765.

[29]Ghany MG, King WC, Lisker-Melman M, et al.Comparison of HBV RNA and hepatitis B core related antigen with conventional HBV markers among untreated adults with chronic hepatitis B in North America[J]. Hepatology, 2021, 74(5):2395-2409.DOI:10. 1002/hep. 32018.

[30]Carey I, Gersch J, Wang B, et al. Pregenomic HBV RNA and hepatitis B core-related antigen predict outcomes in hepatitis B e antigen-negative chronic hepatitis B patients suppressed on nucleos(T)ide analogue therapy[J]. Hepatology, 2020, 72(1):42-57. DOI:10. 1002/hep. 31026.

[31]Vecchi A, Rossi M, Tiezzi C, et al. HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis B[J]. Gut, 2024, 73(10):1737-1748. DOI:10. 1136/gutjnl-2024-332290.

[32]Mu D, Yan L, Tang H, et al. A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system[J]. Biotechnol Lett, 2015, 37(10):2063-2073. DOI:10. 1007/s10529-015-1890-5.

[33]Zhang X, Lu W, Feng Y, et al. A chromogenic in situ hybridization(CISH)assay for detection of HBV RNA,DNA, and cccDNA in liver tissue[J]. Methods Mol Biol, 2024, 2837:137-148. DOI:10. 1007/978-1-0716-4027-2_12.

[34]LebosséF, InchauspéA, Locatelli M, et al.Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients[J]. Sci Rep,2020, 10(1):21097. DOI:10. 1038/s41598-020-78001-1.

[35]Hayashi S, Isogawa M, Kawashima K, et al. Droplet digital PCR assay provides intrahepatic HBV cccDNA quantification tool for clinical application[J]. Sci Rep,2022, 12(1):2133. DOI:10. 1038/s41598-022-05882-9.

[36]Zhong Y, Hu S, Xu C, et al. A novel method for detection of HBVcccDNA in hepatocytes using rolling circle amplification combined with in situ PCR[J].BMC Infect Dis, 2014, 14:608. DOI:10. 1186/s12879-014-0608-y.

[37]Wübbolding M, Lopez Alfonso JC, Lin CY, et al.Pilot study using machine learning to identify immune profiles for the prediction of early virological relapse after stopping nucleos(t)ide analogues in HBeAg-negative CHB[J]. Hepatol Commun, 2020, 5(1):97-111.DOI:10. 1002/hep4. 1626.

[38]Zimmer CL, Rinker F, H?ner Zu Siederdissen C, et al.Increased NK cell function after cessation of long-term nucleos(t)ide analogue treatment in chronic hepatitis B is associated with liver damage and HBsAg loss[J]. J Infect Dis, 2018, 217(10):1656-1666. DOI:10. 1093/infdis/jiy097.

[39]Yan W, Wu D, Wang X, et al. Upregulation of NKG2C+natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavirsuppressed patients with CHB[J]. Antivir Ther, 2015,20(6):591-602. DOI:10. 3851/IMP2953.

[40]Hoogeveen RC, Robidoux MP, Schwarz T, et al.Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection[J]. Gut, 2019, 68(5):893-904.DOI:10. 1136/gutjnl-2018-316644.

[41]Rossi M, Vecchi A, Tiezzi C, et al. Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBVspecific CD8 T cell susceptibility to functional restoration in vitro[J]. Gut, 2023, 72(11):2123-2137. DOI:10. 1136/gutjnl-2022-327202.

[42]李鹏尉，沈宇清.免疫检查点分子在慢性HBV感染中对T细胞功能影响的研究进展[J].病毒学报，2021,37(2):465-470.

[43]Zhang C, Li J, Cheng Y, et al. Single-cell RNA sequencing reveals intrahepatic and peripheral immune characteristics related to disease phases in HBV-infected patients[J]. Gut, 2023, 72(1):153-167. DOI:10. 1136/gutjnl-2021-325915.

[44]Hoogeveen RC, Dijkstra S, Bartsch LM, et al.Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen+infection[J]. J Hepatol, 2022, 77(5):1276-1286. DOI:10. 1016/j. jhep. 2022. 05. 041.

[45]Narmada BC, Khakpoor A, Shirgaonkar N, et al.Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity[J]. J Hepatol, 2024, 81(1):42-61. DOI:10. 1016/j.jhep. 2024. 02. 017.

[46]Li Y, Wen C, Gu S, et al. Differential response of HBV envelope-specific CD4+T cells is related to HBsAg loss after stopping nucleos(t)ide analogue therapy[J]. Hepatology, 2023, 78(2):592-606. DOI:10. 1097/HEP. 0000000000000334.

[47]Cheng Y, Gunasegaran B, Singh HD, et al. Nonterminally exhausted tumor-resident memory HBVspecific T cell responses correlate with relapse-free survival in hepatocellular carcinoma[J]. Immunity,2021, 54(8):1825-1840. e7. DOI:10. 1016/j.immuni. 2021. 06. 013.

[48]Zhao X, Ma S, Wang B, et al. PGG. MHC:toward understanding the diversity of major histocompatibility complexes in human populations[J]. Nucleic Acids Res, 2023, 51(D1):D1102-D1108. DOI:10. 1093/nar/gkac997.

[49]Fu YL, Zhou SN, Hu W, et al. Metabolic interventions improve HBV envelope-specific T-cell responses in patients with chronic hepatitis B[J].Hepatol Int, 2023, 17(5):1125-1138. DOI:10. 1007/s12072-023-10490-4.

[50]Schumann A, Lindemann M, Valentin-Gamazo C, et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients[J]. Transplantation, 2009, 87(1):103-111. DOI:10. 1097/TP. 0b013e31818bfc85.

[51]Yeo W, Chan TC, Leung NWY, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab[J]. J Clin Oncol, 2009, 27(4):605-611. DOI:10. 1200/JCO. 2008. 18. 0182.

[52]Salimzadeh L, Le Bert N, Dutertre CA, et al. PD-1blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. J Clin Invest,2018, 128(10):4573-4587. DOI:10. 1172/JCI121957.

[53]Burton AR, Pallett LJ, McCoy LE, et al. Circulating and intrahepatic antiviral B cells are defective in hepatitis B[J]. J Clin Invest, 2018, 128(10):4588-4603. DOI:10. 1172/JCI121960.

[54]Le Bert N, Salimzadeh L, Gill US, et al. Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B[J]. J Hepatol, 2020, 72(1):34-44. DOI:10. 1016/j.jhep. 2019. 07. 015.

[55]Vanwolleghem T, Adomati T, Van Hees S, et al.Humoral immunity in hepatitis B virus infection:Rehabilitating the B in HBV[J]. JHEP Rep, 2021, 4(2):100398. DOI:10. 1016/j. jhepr. 2021. 100398.

[56]Zhang W, Chen J, Sun W, et al. The impact of hepatitis B surface antigen seroconversion on the durability of functional cure induced by pegylated interferon alpha treatment[J]. Virol J, 2024, 21(1):243. DOI:10. 1186/s12985-024-02522-8.

[57]Zhan Q, Chang L, Wu J, et al. T-cell receptor β chain and B-cell receptor repertoires in chronic hepatitis B patients with coexisting HBsAg and anti-HBs[J].Pathogens, 2022, 11(7):727. DOI:10. 3390/pathogens11070727.

[58]Galson JD, Trück J, Fowler A, et al. Analysis of B cell repertoire dynamics following hepatitis B vaccination in humans, and enrichment of vaccine-specific antibody sequences[J]. EBioMedicine, 2015, 2(12):2070-2079. DOI:10. 1016/j. ebiom. 2015. 11. 034.